MCK McKesson Corporation

McKesson Board of Directors Elects Brad Lerman as New Independent Director

McKesson Corporation (NYSE: MCK) today announced that its Board of Directors has elected Brad Lerman as a new independent director, effective April 24, 2018. With the election of Mr. Lerman, the size of McKesson’s Board of Directors increases from eight to nine members, eight of whom are independent.

“With more than 25 years of experience bringing insights that bridge compliance and government relations with corporate strategy, Brad will be an immediate asset to McKesson’s Board of Directors,” said John H. Hammergren, chairman and chief executive officer, McKesson. “His deep understanding of the healthcare industry and experience in the public and private sectors bring valuable insights to our Board. We have an ongoing commitment to regularly refreshing and strengthening our Board, and Brad is a perfect match for the background we were seeking in this search process.”

“McKesson is a renowned industry leader and the Company possesses a strong foundation for long-term growth. I look forward to working collaboratively with my board colleagues to help guide the Company in advancing its mission to deliver better health to all,” added Brad Lerman.

McKesson regularly engages with its shareholders on corporate governance matters such as board composition and refreshment. “Our director selection process continues to equip the Board with the right mix of qualifications, perspectives, and experiences. The addition of Brad enhances our Board’s overall skill set and supports the execution of McKesson’s strategy, which is designed to deliver long-term growth and sustainable value creation for shareholders,” said Edward Mueller, McKesson’s lead independent director.

Brad Lerman

Mr. Lerman, age 61, is senior vice president, general counsel and corporate secretary for Medtronic. He leads the company’s global legal, government affairs and ethics and compliance functions. Prior to Medtronic, Brad served as executive vice president, general counsel and corporate secretary for the Federal National Mortgage Association (Fannie Mae) and as senior vice president, associate general counsel and chief litigation counsel for Pfizer. For a decade, Mr. Lerman served as a private practice attorney and litigation partner at Winston & Strawn LLP in Chicago. Prior to private practice, he served as a federal prosecutor for the U.S. Department of Justice, where he was an assistant U.S. attorney in the Northern District of Illinois for eight years.

About McKesson Corporation

McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.

EN
30/04/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on McKesson Corporation

Mckesson Corp: 1 director

A director at Mckesson Corp sold 2,725 shares at 990.000USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Shifting to Neutral Near-Term as Chop Continues We are shifting our near-term outlook to neutral on the S&P 500 (SPX), after being bullish for all but one week since 4/22/25 (we went neutral 11/19/25-11/25/25). Choppy consolidation has continued between support at 6780-6824 and resistance at 7000, and a neutral near-term outlook is appropriate until there is a decisive break in either direction. The Russell 2000 (IWM) remains much more attractive, and we remain constructive near-term on IWM as ...

McKesson Corporation: Update to credit analysis

McKesson's reflects its position as one of the largest drug distributors in the US, as wells as its modest financial leverage, partially offset by low margins and high customer concentration

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of McKesson Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 November 2025 in which we reassessed the appropriateness of the ratings in the cont...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of McKesson Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 25 February 2025 in which we reassessed the appropriateness of the ratings in the cont...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch